Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

One Year of Newborn Screening for SMA – Results of a German Pilot Project
Katharina Vill, Heike Kölbel, Oliver Schwartz, et al.
Journal of Neuromuscular Diseases (2019) Vol. 6, Iss. 4, pp. 503-515
Open Access | Times Cited: 163

Showing 1-25 of 163 citing articles:

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1381-1389
Open Access | Times Cited: 215
Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
David Schorling, Astrid Pechmann, Janbernd Kirschner
Journal of Neuromuscular Diseases (2019) Vol. 7, Iss. 1, pp. 1-13
Open Access | Times Cited: 211
Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Brunhilde Wirth, Mert Karakaya, Min Jeong Kye, et al.
Annual Review of Genomics and Human Genetics (2020) Vol. 21, Iss. 1, pp. 231-261
Closed Access | Times Cited: 206
Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010
J.G. Loeber, Dimitris Platis, Rolf Zetterström, et al.
International Journal of Neonatal Screening (2021) Vol. 7, Iss. 1, pp. 15-15
Open Access | Times Cited: 184
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Tamara Dangouloff, Eva Vrščaj, Laurent Servais, et al.
Neuromuscular Disorders (2021) Vol. 31, Iss. 6, pp. 574-582
Closed Access | Times Cited: 147
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Katharina Vill, Oliver Schwartz, Astrid Blaschek, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 140
Spinal Muscular Atrophy: In the Challenge Lies a Solution
Brunhilde Wirth
Trends in Neurosciences (2021) Vol. 44, Iss. 4, pp. 306-322
Closed Access | Times Cited: 136
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
Karolina Aragon‐Gawinska, Charlotte Mouraux, Tamara Dangouloff, et al.
Genes (2023) Vol. 14, Iss. 7, pp. 1377-1377
Open Access | Times Cited: 47
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, et al.
JAMA Pediatrics (2024) Vol. 178, Iss. 6, pp. 540-540
Closed Access | Times Cited: 26
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Sonia Messina, Maria Sframeli
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2222-2222
Open Access | Times Cited: 135
Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
Melissa C. Keinath, Devin E. Prior, Thomas W. Prior
The Application of Clinical Genetics (2021) Vol. Volume 14, pp. 11-25
Open Access | Times Cited: 102
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Janbernd Kirschner, Nina Butoianu, Nathalie Goemans, et al.
European Journal of Paediatric Neurology (2020) Vol. 28, pp. 38-43
Open Access | Times Cited: 89
Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA
Lingling Kong, David Valdivia, Christian M. Simon, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 578
Open Access | Times Cited: 84
Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
Tamara Dangouloff, Camille Botty, Charlotte Beaudart, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 83
How to proceed after “negative” exome: A review on genetic diagnostics, limitations, challenges, and emerging new multiomics techniques
Saskia B. Wortmann, Machteld M. Oud, Mariëlle Alders, et al.
Journal of Inherited Metabolic Disease (2022) Vol. 45, Iss. 4, pp. 663-681
Open Access | Times Cited: 58
Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study
Ilaria Bitetti, Valentina Lanzara, Giovanna Margiotta, et al.
Gene Therapy (2022) Vol. 30, Iss. 7-8, pp. 592-597
Open Access | Times Cited: 43
Newborn Screening for Spinal Muscular Atrophy in New York State
Bo Hoon Lee, Stella Deng, Claudia A. Chiriboga, et al.
Neurology (2022) Vol. 99, Iss. 14
Open Access | Times Cited: 41
Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies
Ilaria Angilletta, Rossella Ferrante, Roberta Giansante, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14873-14873
Open Access | Times Cited: 26
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
Diana Weidlich, Laurent Servais, Imran Kausar, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1220
Open Access | Times Cited: 24
Spinal Muscular Atrophy Update in Best Practices
Mary Schroth, J. Deans, Kapil Arya, et al.
Neurology Clinical Practice (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 12
Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam—Part 2: Experience from a nusinersen clinical study
Kathie M. Bishop, Jacqueline Montes, Richard S. Finkel
Muscle & Nerve (2017) Vol. 57, Iss. 1, pp. 142-146
Closed Access | Times Cited: 69
Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy
Denise M. Kay, Colleen F. Stevens, April Parker, et al.
Genetics in Medicine (2020) Vol. 22, Iss. 8, pp. 1296-1302
Open Access | Times Cited: 66
Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening – Opportunity or Burden?1
Wolfgang Müller‐Felber, Katharina Vill, Oliver Schwartz, et al.
Journal of Neuromuscular Diseases (2020) Vol. 7, Iss. 2, pp. 109-117
Open Access | Times Cited: 56
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
François Boemer, Jean‐Hubert Caberg, Pablo Beckers, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 56
Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme
Arlene D’Silva, Didu Kariyawasam, Stephanie Best, et al.
Developmental Medicine & Child Neurology (2021) Vol. 64, Iss. 5, pp. 625-632
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top